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To determine if alterations in endothelial prostaglandin produc-
tion occur after long-term cocaine use, 26 New Zealand White
rabbits were randomized to a low fat diet with (n =12) or without
(n =14) daily intravenous cocaine (2 mg/kg body weight). Rabbits
were killed at 6 or 12 weeks. Segments of aorta were examined in
blinded manner for histologic changes. Additional slices were
incubated in oxygenated Krebs butTer and release of 6-keto-
prostaglandin Fla , thromboxane B2 and prostaglandin E2 was
assayed by radioimmunoassay.
Minimal intimal histologic changes were seen in the aorta of
three cocaine-treated rabbits. At 12 weeks 6-keto-prostaglandin
Fla was increased in the cocaine group (p =0.063) as compared
with levels in the control group. When rabbits killed at 6 and 12
Cocaine abuse is a major health hazard in the United States.
More than 22 million Americans have tried cocaine at least
once, and 5 million are current users (1). Recent reports
(1-5) document that cocaine abuse can result in myocardial
ischemia and infarction even in the absence of significant
coronary artery disease. Myocardial ischemia may occur
immediately after the use of cocaine (3,4) or hours to days
later (6). The pathophysiologic mechanism or mechanisms
responsible for such a diverse temporal relation between
cocaine ingestion and myocardial events are unknown.
However, cocaine-induced coronary artery vasoconstriction
has been reported in patients after intranasal cocaine (7).
This vasoconstriction appears to be primarily alpha-
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weeks were considered together, increases in thromboxane B2
(p =0.044) and a trend to increased prostaglandin E2 (p =0.083)
were seen in the cocaine group. The ratio of thromboxane B2 to
6-keto-prostaglandin Fla was increased in the cocaine group
compared with that in the control group (p < 0.02).
These data suggest that an increase in prostaglandin produc-
tion occurs in the vascular endothelium of rabbits ingesting
cocaine before gross histologic changes are evident. In addition,
thromboxane B2 increases disproportionately with respect to
6-keto-prostaglandin Fla , suggesting that a milieu for thrombosis
may exist in users of cocaine.
(J Am Coli CardioI1992;19:696-703)
adrenergically mediated because it can be blocked with the
alpha-adrenergic antagonist, phentolamine (7). Furthermore,
cocaine-induced vasoconstriction is more pronounced at
sites of angiographically visible atherosclerosis than at sites
of angiographically normal coronary arteries (8). This obser-
vation suggests that endothelial modulation of coronary
vasoconstriction may play an important role in the patho-
physiologic mechanism of cocaine-induced vasoconstric-
tion. It has also been suggested (4,5,9) that cocaine may
potentiate platelet aggregation and thereby contribute to the
development of coronary artery thrombosis.
We (10) have shown that patients who have a history of
chest pain temporally related to cocaine use frequently have
evidence of endothelial dysfunction (that is, acetylcholine-
induced coronary vasoconstriction). We (10) have also re-
ported histologic evidence of accelerated atherosclerosis in
the coronary arteries of autopsy subjects who had a history
of chronic cocaine abuse. Thus, patients who have chest
pain temporally related to cocaine use frequently have
evidence of endothelial dysfunction that may be related to
functional or structural endothelial changes, or both.
Work from other investigators (11) has demonstrated a
decrease in in vitro 6-keto-prostaglandin F1a (a stable me-
tabolite of prostacyclin [PGI2]) production in umbilical ar-
teries from pregnant cocaine abusers. These investigators
(11) also found a dose-dependent decrease in phospholipase
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Az activity in vitro with very large cocaine doses. Because
previous work from our group (12,13) has shown that throm-
boxane Az is an important mediator of the conversion from
stable to unstable angina, we were interested in examining
the role of prostaglandins in promoting cocaine-induced
ischemia.
Therefore, the purpose of this study was to determine if
cocaine induces biochemical or histologic arterial changes in
rabbit aorta. Our hypothesis was: Chronic cocaine adminis-
tration alters endothelial prostaglandin production or pro-
motes the development of histologic endothelial abnormali-
ties, or both.
Methods
Protocol. Twenty-six New Zealand White rabbits were
randomized to a low cholesterol, low fat diet with (n = 12,
group A) or without (n = 14, group B) a daily dose of
intravenous cocaine (2 mg/kg body weight). This dose was
based on previous human studies (7) demonstrating 2 mg/kg
to be safe, yet capable of producing a hemodynamically
significant effect. At 6 weeks, six group A and six group B
rabbits were weighed in blinded manner and killed. At 12
weeks of cocaine treatment, six group A and eight group B
rabbits were killed in a similar fashion. This protocol was
approved by the Animal Studies Subcommittee of the Dallas
Veterans Administration Medical Center, July 1990 and
conforms to the "Position of the American Heart Associa-
tion on Research Animal Use."
Aorta tissue preparation. On the animal's death, a 3- to
5-mm cross section of aorta was removed and fixed in 10%
buffered formalin for eventual histologic examination. The
section was stained with hematoxylin-eosin and examined
histologically by a pathologist (S.E.D.) who had no knowl-
edge of the treatment randomization.
At the time of induced death, a 3- to 5-mm transverse
section of aorta adjacent to the histologic slice was removed
for assessment of prostaglandin production. The section was
not selected on the basis of prior histologic examination. It
was immediately suspended in Krebs-Henseleit buffer (pH
7.4, 37°C) and used to examine the synthesis and release of
prostanoids from group A and group B aortas. At 5, 15, 30
and 60 min after suspension in the buffer, 100 JLl of buffer
was removed and immediately frozen at -80°C. These
samples were stored at -80°C until radioimmunoassay could
be performed to analyze for prostanoids. After the last
sample was collected, the slices were analyzed for protein
content. The tissue slices were weighed and homogenized in
O.l-M potassium phosphate buffer with 0.01% triton with a
Ultraturrex homogenizer (Tekmar) for 150 s. The homoge-
nate was spun at 2,000 rpm for 5 min and the supernatant
decanted and analyzed for protein content by the method of
Lowry et al. (14).
Radioimmunoassay. Our methodology for radioimmuno-
assay of 6-keto-prostaglandin Fla, thromboxane Bz and
prostaglandin Ez has been previously described (15). In
brief, these prostanoids were measured from the unextracted
effluent perfusate by radioimmunoassay. The antiserum does
not distinguish between prostaglandin Eland prostaglandin
Ez. All samples and standards were measured in duplicate.
Antisera were obtained in lyophilized form from Dr.
Lawrence Levine, Department of Biochemistry, Brandeis
University (6-keto-prostaglandin Fla and thromboxane Bz)
and Advanced Magnetics, Cambridge, Massachusetts (pros-
taglandin Ez). Dilutions in assay buffer of 1:5,000, 1:8,000
and 1: 12,000 for prostaglandin Ez, 6-keto-prostaglandin Fla
and thromboxane Bz, respectively, were used to obtain 40%
to 60% binding of a zero standard "blank." Cross-reactivity
of antisera from Dr. Levine has been published previously
(16). The cross-reactivity of 6-keto-prostaglandin Fla is < 1%
to prostaglandin Fza , prostaglandin Dz, thromboxane Bzand
13,14-H2-prostaglandin Ez. The cross-reactivity of throm-
boxane Bz antiserum is <1% to prostaglandin Fza, prosta-
glandin Dz, 6-keto-prostaglandin Fza, 6-keto-prostaglandin
F1a and 13,14-H2-prostaglandin Ez. Cross-reactivity of the
prostaglandin Ezantiserum is given by Advanced Magnetics
as 50% to prostaglandin EI and <1% to 6-keto-prostaglandin
Fla'
The standard curve was constructed with use of the
smoothed-spline function (RIA computer software package
SecuRIA, Packard). Unbound, unabsorbed tracer (referred
to as "nonspecific binding") was quantified in tubes contain-
ing only labeled ligand and dextran-coated charcoal. Interas-
say and intra-assay variation was 7% to 9% for 6-keto-
prostaglandin F1a and thromboxane Bz and 14% to 15% for
prostaglandin Ez. Sensitivity (the amount of unlabeled stan-
dard causing 5% reduction from maximal binding of the
blank) was approximately 8 pg.
Statistical analysis. Differences in prostaglandin produc-
tion between groups A and B were assessed (at 5, 15,30 and
60 min of suspension time in buffer) by a repeated measures
analysis of variance. As the thromboxane Bz data exhibited
significant heteroscedasticity, a logarithmic (base 10) trans-
formation was used before analysis of data to achieve
common variances between the two groups. Because several
rabbits exhibited no thromboxane release (that is, 0 JLg/mg
protein), their thromboxane Bzvalues were set to 0.01 JLg/mg
protein and then 0.001 JLg/mg protein to avoid losing data
with a logarithmic transformation (loglo 0 does not exist).
The data were analyzed with use ofboth values. Because the
lower limit of sensitivity of the assay is 0.00008 JLg/ml
(approximately 0.00032 JLg/mg protein, assuming 0.63 mg
protein per sample, which was the mean sample protein
content), these were reasonably low values for thromboxane
detection. The effect of the presence of intimal changes on
prostaglandin production was assessed by a 2-factor (intimal
changes, group A vs. B) analysis of variance at 5, 15 and
30 min. Differences in heart weight and body weight were
assessed by an unpaired Student t test. Nominal variables
were assessed by contingency table analysis. Statistical
significance was established at p < 0.05 and a trend at p <
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0.10. All results are expressed as mean values ± 1SD unless
otherwise specified.
Results
Group characteristics at induced death. Group A and B
rabbits did not differ in age or gender (chi-square = 0.26). At
the time ofdeath, there was no difference in body weight (3.5
± 0.2 vs. 3.7 ± 0.1 kg, group A vs. group B) or heart weight
(6.9 ± 1.0 vs. 6.2 ± 0.8 g). In group A rabbits heart weight
was indexed to body weight and was slightly higher than that
of group B rabbits (2 ± 0.3 vs. 1.7 ± 0.2 g/kg), although this
difference did not reach statistical significance (p = 0.13).
Prostaglandin results (Table 1). At 6weeks a strong trend
(p = 0.082) of increased thromboxane Bz production was
found in the cocaine-treated rabbits, although there were no
differences between groups in 6-keto-prostaglandin FI a or
prostaglandin Ez release (Fig. 1). At 12 weeks the cocaine
group had increased 6-keto-prostaglandin Fla release (p =
0.063) but no significant differences in thromboxane Bz (p =
0.29) or prostaglandin Ez release with respect to the control
group (Fig. 2). Although the mean values for thromboxane
Bz production were 23 to 34 times higher in the cocaine
group, this difference did not reach statistical significance.
No significant differences between groups in prostaglandin
Ezproduction were seen at 12 weeks (p = 0.12), although the
cocaine group had mean values 3 to 10 times larger at both 6
and 12 weeks. This finding was due to a subgroup of rabbits
with very large prostaglandin production. When all 26 rab-
bits (with 6 and with 12 weeks of treatment) in the two
groups were studied, a significant increase in thromboxane
Bzproduction was seen overall (Fig. 3). Overall, no increase
in 6-keto-prostaglandin Fla was found when all rabbits in
both groups were studied. For those rabbits with a throm-
boxane Hz release of 0 JLg/mg protein, when a value of
0.001 JLg/mg protein was used (instead of0.01 JLg/mg protein)
to calculate a logarithmic transformation for statistical anal-
ysis, no difference (0.01 vs. 0.001 JLg/mg protein) in p values
occurred.
The ratio ofthromboxane B2 to 6-keto-prostaglandin F1a
release was determined to ascertain if the increased prosta-
glandin production was disproportional (Fig. 4). Previous
investigators (17,18) have used a ratio of prostanoids to
examine relative changes in these substances. The cocaine
group had an 8- to 13-fold higher mean value for this ratio at
5, 15, 30 and 60 min of prostaglandin production (p < 0.02).
These data suggest that aortic thromboxane Bz (which
reflects thromboxane Az production) increases in some
rabbits with long-term cocaine use. In addition, 6·keto-
prostaglandin Fla (which reflects prostacyclin production)
and perhaps prostaglandin Ez may increase with chronic
cocaine exposure. In some rabbits chronic cocaine use
produced disproportionate increases in thromboxane Bz as
compared with 6-keto-prostaglandin Fla'
Histologic findings. Three of the rabbits killed at 6 weeks
had minimal evidence of histologic changes consistent with
early intimal proliferation (Fig. 5). Although all three of
these rabbits were in group A, we were unable to establish a
correlation between cocaine use and development of intimal
changes because of the small number of rabbits with changes
(chi-square = 3.96, p = 0.047; chi-square with continuity
correction = 1.89, p =0.17). Because the number of rabbits
with histologic changes was small, there was no relation of
intimal changes to alterations in either 6-keto-prostaglandin
Fla' thromboxane Bz or prostaglandin Ez.
Discussion
Our study demonstrates that cocaine abuse causes in-
creases in vascular prostaglandin production in rabbits.
Furthermore, these data suggest a possible disproportionate
increase in thromboxane Az production as compared with
prostacyclin production. These biochemical changes oc-
curred despite the absence of significant histologic changes.
Previous studies. Previous studies of cocaine-induced
ischemic heart disease (5,7,19) have focused on pharmaco-
logic properties of cocaine that promote vasoconstriction.
Such studies, although important, fail to explain why myo-
cardial ischemic events often occur days or months after
cocaine ingestion (6). We (10) have previously demonstrated
that cocaine abuse is associated with accelerated atheroscle-
rosis and a dysfunctional endothelial response to acetylcho-
line, suggesting depressed release of one or more endotheli-
um-derived relaxation factors. Although these previously
published data (10) demonstrated that chronic cocaine abuse
may be associated with functional and anatomic abnormali-
ties of the coronary artery endothelium, the data from our
current study suggest that biochemical abnormalities may
also be present. Because previous investigations (20,21)
have shown increases in prostacyclin and thromboxane
production in the presence of atherosclerosis, an increase in
prostaglandin production might not be unexpected in the
presence of intimal proliferation or endothelial injury. How-
ever, we found that these biochemical changes were inde-
pendent of histologic changes.
Speculation about why cocaine may cause ischemia. Al-
though prior studies (3-5,7,19) have suggested that cocaine
causes myocardial infarction through both norepinephrine-
mediated alpha-adrenergic coronary vasoconstriction and
direct coronary vasoconstriction, it is unclear why coronary
vasospasm and myocardial infarction occur in association
with acute or chronic use of cocaine in some persons but not
in others. Furthermore, the occurrence of myocardial infarc-
tion or ischemia well after cocaine ingestion in some patients
(6) suggests that these events are not simply a direct conse-
quence of cocaine-mediated coronary vasoconstriction in
many cases. The absence of chest pain or myocardial
infarction in some users of "crack" or freebase cocaine
(who have high serum levels of cocaine) and its presence in
some persons who inhale or "snort" cocaine (and have
lower serum levels) also suggests that infarction in users is
not just a dose-related phenomenon of cocaine-induced
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Table 1. Results at 6 and 12 Weeks for Prostaglandin Production From Group A(cocaine-treated) and B (untreated) Rabbit Aortas
5 Min 15 Min 30 Min 60 Min p Value
6 Weeks
6-keto-prostaglandin FI a
Group A (n = 6) 150 ± 137 166 ± 96 136 ± 75 210 ± 106 0.27
Group B (n = 6) 151 ± 98 334 ± 277 327 ± 291 262 ± 163
Thromboxane B2
Group A (n = 6) 63 ± 43 5.0 ± 4.1 3.2 ± 2.5 4.8 ± 3.4 N/A
Group B (n = 6) 4.2 ± 6.6 3.9 ± 6 1.2 ± 2.1 2.1 ± 3.2
Log lO thromboxane Bz
Group A (n = 6) 0.54 ± 0.76* 0.24 ± 1.14 0.11 ± 1.06t 0.26 ± 1.13 0.082
Group B (n = 6) -1.63 ± 2.12 -0.98 ± 1.58 -1.16 ± 1.31 -1.07 ± 1.44
Prostaglandin Ez
Group A (n = 6) 203 ± 13.6 17.4 ± 18 21.4 ± 25.4 32.5 ± 40.7 0.53
Group B (n = 6) 21.2 ± 19.8 17.6 ± 8.7 12.8 ± 6.1 12.7 ± 7.6
Thromboxane Bz/6-keto-prostaglandin Fla
Group A (n = 6) 0.12 ± 0.17 0.036 ± 0.035t 0.032 ± 0.029 0.027 ± 0.017 0.26
Group B (n = 6) 0.02 ± 0.03 0.007 ± 0.012 0.005 ± 0.01 0.008 ± 0.012
12 Weeks
6-keto-prostaglandin Fla
Group A (n = 6) 427 ± 1m 769 ± 270t 590 ± 182 571 ± 140 0.063
Group B (n = 8) 204 ± 107 365 ± 158 579 ± 471 590 ± 275
Thromboxane Bz
Group A (n = 6) 51.7 ± 88.8 44.4 ± 75.6 36.4 ± 62 323 ± 51.5 N/A
Group B (n = 8) 1.7±1.7 1.3 ± 1.4 1.3±1.3 1.4 ± 1.2
Log lO thromboxane Bz
Group A (n = 6) 0.51 ± 1.89 0.65 ± 1.51 03 ± 1.61 0.48 ± 1.48 0.29
Group B (n = 8) -0.59 ± 1.54 -0.63 ± 1.19 -0.61 ± 1.19 -0.07 ± 0.87
Prostaglandin Ez
Group A (n = 6) 26.2 ± 33.lt 31.3 ± 46.5 28.5 ± 43.2 33.1 ± 46.4 0.12
Group B (n = 8) 33 ± 4.6 4.8 ± 4 2.9 ± 3.6 9.8 ± 13
Thromboxane Bz/6-keto-prostaglandin FI a
Group A (n = 6) 0.133 ± 0.244 0.041 ± O.06t 0.048 ± 0.08 0.05 ± 0.079 0.16
Group B (n = 8) 0.008 ± 0.008 0.003 ± 0.003 0.002 ± 0.002 0.003 ± 0.003
6 and 12 Weeks (all rabbits)
6-keto-prostaglandin FI a
Group A (n = 12) 289 ± 188t 467 ± 369 363 ± 272 390 ± 222 0.88
Group B (n = 14) 181 ± 103 352 ± 208 471 ± 411 450 ± 282
Thromboxane Bz
Group A (n = 12) 29 ± 64.5 24.7 ± 55.1 19.8 ± 45.3 18.6 ± 37.7 N/A
Group B (n = 14) 2.8 ± 4.5 2.4 ± 4.1 1.3 ± 1.6 1.7 ± 2.2
Log lO thromboxane Bz
Group A (n = 12) 0.53 ± 1.37* 0.44 ± 1.29* 0.21 ± 1.3* 037 ± 1.26t 0.044
Group B (n = 14) -1.04 ± 1.82 -0.78 ± 1.33 -0.85 ± 1.22 -0.53 ± 1.23
Prostaglandin Ez
Group A (n = 12) 233 ± 243 243 ± 34.4 25 ± 34t 32.8 ± 41.6t 0.083
Group B (n = 14) 11 ± 15.7 103 ± 9 7.2 ± 6.9 11 ± 10.8
Thromboxane Bz/6-keto-prostaglandin F1a
Group A (n = 12) 0.126 ± 0.2* 0.038 ± 0.047* 0.04 ± 0.058* 0.Q38 ± 0.056* 0.019
Group B (n = 14) 0.014 ± 0.022 0.005 ± 0.008 0.003 ± 0.007 0.005 ± 0.008
*p < 0.05, tp < 0.1 tp < 0.005 versus group B. Values are expressed as ng prostaglandin/mg protein (mean ± I SO). N/A = not applicable because of
heteroscedasticity.
vasospasm. In addition, recent studies (22,23) have chal-
lenged the hypothesis that cocaine causes vasoconstriction
or vasospasm in humans. Thus, other predisposing or per-
missive factors may create a milieu facilitating cocaine-
induced vasoconstriction or thrombosis, or both. Such a
milieu may permit vasoconstriction or thrombus formation
to occur, even without the presence of cocaine.
We propose that coronary tone is maintained through the
balance of various endothelial and humoral factors (13,24-
28). Several of these factors are responsible for coronary
100
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Figure 2. Changes in prostaglandin production at 12 weeks. At 12
weeks release of 6-keto-prostaglandin Fla (PGFla), thromboxane Bz
and prostaglandin Ez(PGEz)were assayed at 5, 15,30 and 60 min for
groups A (+) and B (0). No differences were seen in prostaglandin
Ez•Although a 23- to 34-fold increase in mean values for thrombox-
ane Bzwas seen in the cocaine group, this difference did not reach
statistical difference (p = 0.29). A strong trend to increased 6-keto-
prostaglandin F1a release was found in the cocaine group (p =
0.063). Values are expressed as mean values ± SEM.
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Figure 1. Changes in prostaglandin production at 6 weeks. At 6
weeks release of 6-keto-prostaglandin Fla (PGFla), thromboxane Bz
and prostaglandin Ez(PGEz)were assayed at 5,15,30 and 60 min for
groups A (+) and B (0). No differences were seen in 6-keto-
prostaglandin F1a and prostaglandin Ez. A trend to increased
thromboxane Bz (p = 0.082) was found at 6 weeks. Values are
expressed as mean values ± SEM.
constriction, including thromboxane A2, norepinephrine, sero-
tonin, neuropeptide Y and endothelin. Among the vasodila-
tors are endothelium-derived relaxation factors, substance
P, vasoactive intestinal peptide, prostacyclin, nucleosides
and nucleotides (adenosine triphosphate and diphosphate
and adenosine), histamine, serotonin (with intact endothe-
lium) and bradykinin. Arelative lack of endothelium-derived
relaxation factors and an increase in the ratio of thrombox-
ane A2 to prostacyclin may predispose a person to vasocon-
striction, vasospasm or thrombosis, especially in the pres-
ence of a vasoconstricting agent such as cocaine.
Cocaine-induced vasospasm and thrombosis. Thus, co-
caine abuse may induce an altered endothelial milieu that
permits vasoconstriction or thrombosis, or both. Such ab-
normalities include reduced release of endothelium-derived
relaxation factors and increased production of prostaglan-
dins, with disproportionate increases in thromboxane (com-
pared with prostacyclin). As we (10) and others (29) have
previously shown atherosclerosis in postmortem studies in
some abusers, flow may be further altered by these lesions.
Development of these lesions may also predispose to throm-
bosis and infarction. Our group (8) has previously demon-
strated accentuated vasoconstriction in response to cocaine
administration at sites ofatherosclerosis in noncocaine abus-
ers undergoing cardiac catheterization. Thus, cocaine ad-
ministration, in the presence of this altered milieu, may
predispose to vasospasm and thrombosis. Whereas these
patients often have angiographically normal coronary arter-
ies (5,10), they may have intimal changes that are not
detected by angiography. Although the ability of cocaine to
induce vasoconstriction may be endothelium independent
(5), dysfunctional endothelium may playa role in modulating
coronary vasoconstriction in the presence of cocaine or may
promote in situ thrombosis and vasoconstriction even in the
absence of cocaine.
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Figure 3. Overall changes in prostaglandin production at 6 and 12
weeks. Release of 6-keto-prostaglandin FIll (PGF1a), thromboxane
B2 and prostaglandin E2 (PGE2) were assayed for all the rabbits
(those killed at 6weeks and those killed at 12 weeks) at 5, 15,30 and
60 min for groups A (+) and B (0). No differences were seen in
6-keto-prostaglandin Fill release. However, increases in thrombox-
ane B2 (p = 0.044) and a trend toward increased prostaglandin E2
(p = 0.083) were detected. Values are expressed as mean values ±
SEM.
Figure 4. The ratios of thromboxane B2 to 6-keto-prostaglandin FIll
(TxBi6-keto PGF la) are shown for rabbits killed at 6 weeks or 12
weeks and the total group ofrabbits killed at each time period at 5,
15, 30 and 60 min for groups A (+) and B (0). Although this ratio
was increased at 6 and 12 weeks, this increase did not reach
statistical significance until all rabbits were analyzed (p < 0.019).
This milieu may change somewhat in the initial stages of
cocaine abuse as intimal proliferation or accelerated athero-
sclerosis develops. In our study the increase in thromboxane
was greater at 12 than at 6 weeks in a subgroup of rabbits. In
addition, in some rabbits 6-keto-prostaglandin Fla was un-
changed or slightly decreased at 6 weeks but was increased
at 12 weeks. It is unclear what the effect of cocaine is after
12 weeks.
Study limitations. The major limitation of this study was
the short time period in which the rabbits were treated. Most
drug abusers have a much longer history of abuse and many
may use cocaine more than once each day. We might have
seen more intimal changes and more pronounced changes in
prostaglandin production had we studied more frequent and
longer periods of cocaine administration. In addition, be-
cause the control rabbits (group B) received no injections
such as saline solution, we cannot rule out an effect of the
injecting process on the endothelium. We used pure indus-
trial grade cocaine that contained none of the many impuri-
ties found in street-purchased cocaine. Such impurities may
have additional effects on the development of intimal his-
tologic changes and on prostaglandin production.
Because our preparations were devoid of circulating
platelets and white blood cells, the contribution of these
elements to prostaglandin production was not assessed. In
vivo, at sites of endothelial injury and constriction, platelets
may aggregate and release mediators that promote sponta-
neous reductions in coronary blood flow and thrombosis
(12,13,30). Among these mediators are serotonin and throm-
boxane Az. Thus, our assessment of endothelial thrombox-
ane release may have underestimated the total amount of
thromboxane Az present in the coronary artery in vivo.
However, the relative increase in vascular thromboxane
production, especially in the presence of coronary vasocon-
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Figure 5. Histologic changes in the rabbit aorta can be seen in these
photomicrographs. Above, a normal rabbit aorta (group B). Below, a
cross section of aorta from a cocaine-treated rabbit with early
intimal hyperplasia and vacuolation. The arrows point to the abnor-
mal changes. Hematoxylin-eosin x50, reduced by 25%.
striction due to cocaine use, may initiate or perpetuate
platelet mediator release, promoting a cascade of aggrega-
tion and further mediator release.
Although the buffer, which was changed at 5, 15, 30 and
60 min, could be a weak stimulus for prostaglandin release,
it should have effected equal changes in the two prospec-
tively randomized groups. Our reproducibility data have
been previously published (15).
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